よむ、つかう、まなぶ。
04資料1-2 森野委員提出資料（成人用肺炎球菌ワクチンファクトシート追補版） (33 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_76211.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第36回 9／17）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
36(11): 1477–83.
45.
Farrar JL, Childs L, Ouattara M, et al. Systematic Review and Meta-Analysis of the Efficacy and
Effectiveness of Pneumococcal Vaccines in Adults. Pathogens 2023; 12(5).
46.
医薬品医療機器総合機構. バクニュバンス水性懸濁注シリンジ 審査報告書. 2022/09/01.
https://www.pmda.go.jp/drugs/2022/P20220927001/170050000_30400AMX00410000_A100_1.pdf (accessed
2026/7/31).
47.
医薬品医療機器総合機構. プレベナー20 水性懸濁注 審査報告書. 2024/09/13.
https://www.pmda.go.jp/drugs/2024/P20240829003/672212000_30600AMX00115_A100_2.pdf (accessed
2026/7/31).
48.
Kobayashi M, Pilishvili T, Farrar JL, et al. Pneumococcal Vaccine for Adults Aged ≥19 Years:
Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR
Recomm Rep 2023; 72(3): 1–39.
49.
Centers for Disease Control and Prevention. Pneumococcal Vaccination: Information for Health Care
Providers. 2022. https://www.cdc.gov/vaccines/hcp/by-disease/pneumo.html (accessed 2026/7/31).
50.
Miles AC, Vojicic J, Peyrani P, et al. Real-world effectiveness of 20-valent pneumococcal conjugate
vaccine against all-cause outcomes among Medicare beneficiaries aged 65 years and older in the USA: a
retrospective cohort study. Lancet Infect Dis 2026.
51.
Haute Autorité de Santé（フランス高等保健機構）. Stratégie de vaccination contre les infections
invasives à pneumocoques : place du vaccin CAPVAXIVE chez l’adulte [機械翻訳：Vaccination Strategy
Against Invasive Pneumococcal Infections: The Role of CAPVAXIVE in Adults]. 2025. https://www.hassante.fr/jcms/p_3634637/fr/strategie-de-vaccination-contre-les-infections-invasives-a-pneumocoques-placedu-vaccin-capvaxive-chez-l-adulte (accessed 2026/7/31).
52.
Zheng X, Liu M, Ding A, et al. Post-marketing safety surveillance of pneumococcal vaccines: a real-
world pharmacovigilance study using the U.S. vaccine adverse event reporting system (VAERS) database. Front
Cell Infect Microbiol 2025; 15: 1635180.
53.
Centers for Disease Control and Prevention. Grading of Recommendations, Assessment,
Development, and Evaluation (GRADE): 21-valent Pneumococcal Conjugate Vaccine (PCV21) Use among
Adults Aged ≥19 Years Who Currently Have a Recommendation to Receive a Pneumococcal Conjugate
Vaccine. 2024/09/12. https://www.cdc.gov/acip/grade/pcv21-adults-19-and-older.html (accessed 2026/7/31).
54.
Centers for Disease Control and Prevention. Grading of Recommendations, Assessment,
Development, and Evaluation (GRADE): 21-valent Pneumococcal Conjugate Vaccine (PCV21) Use among
Adults Aged 50–64 Years Who Currently Do Not Have a Risk-Based Pneumococcal Vaccine Indication.
2024/05/27. https://www.cdc.gov/acip/grade/pcv21-non-risk-based-adults-50-64.html (accessed 2026/7/31).
55.
Health Canada. Summary Basis of Decision for Capvaxive. 2025/04/04 2024. https://dhpp.hpfb-
dgpsa.ca/review-documents/resource/SBD1734463856248 (accessed 2026/7/31).
56.
European Medicines Agency. Capvaxive: EPAR - Public assessment report. 2025/01/30 2025.
https://www.ema.europa.eu/en/documents/assessment-report/capvaxive-epar-public-assessmentreport_en.pdf (accessed 2026/7/31).
33
45.
Farrar JL, Childs L, Ouattara M, et al. Systematic Review and Meta-Analysis of the Efficacy and
Effectiveness of Pneumococcal Vaccines in Adults. Pathogens 2023; 12(5).
46.
医薬品医療機器総合機構. バクニュバンス水性懸濁注シリンジ 審査報告書. 2022/09/01.
https://www.pmda.go.jp/drugs/2022/P20220927001/170050000_30400AMX00410000_A100_1.pdf (accessed
2026/7/31).
47.
医薬品医療機器総合機構. プレベナー20 水性懸濁注 審査報告書. 2024/09/13.
https://www.pmda.go.jp/drugs/2024/P20240829003/672212000_30600AMX00115_A100_2.pdf (accessed
2026/7/31).
48.
Kobayashi M, Pilishvili T, Farrar JL, et al. Pneumococcal Vaccine for Adults Aged ≥19 Years:
Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR
Recomm Rep 2023; 72(3): 1–39.
49.
Centers for Disease Control and Prevention. Pneumococcal Vaccination: Information for Health Care
Providers. 2022. https://www.cdc.gov/vaccines/hcp/by-disease/pneumo.html (accessed 2026/7/31).
50.
Miles AC, Vojicic J, Peyrani P, et al. Real-world effectiveness of 20-valent pneumococcal conjugate
vaccine against all-cause outcomes among Medicare beneficiaries aged 65 years and older in the USA: a
retrospective cohort study. Lancet Infect Dis 2026.
51.
Haute Autorité de Santé（フランス高等保健機構）. Stratégie de vaccination contre les infections
invasives à pneumocoques : place du vaccin CAPVAXIVE chez l’adulte [機械翻訳：Vaccination Strategy
Against Invasive Pneumococcal Infections: The Role of CAPVAXIVE in Adults]. 2025. https://www.hassante.fr/jcms/p_3634637/fr/strategie-de-vaccination-contre-les-infections-invasives-a-pneumocoques-placedu-vaccin-capvaxive-chez-l-adulte (accessed 2026/7/31).
52.
Zheng X, Liu M, Ding A, et al. Post-marketing safety surveillance of pneumococcal vaccines: a real-
world pharmacovigilance study using the U.S. vaccine adverse event reporting system (VAERS) database. Front
Cell Infect Microbiol 2025; 15: 1635180.
53.
Centers for Disease Control and Prevention. Grading of Recommendations, Assessment,
Development, and Evaluation (GRADE): 21-valent Pneumococcal Conjugate Vaccine (PCV21) Use among
Adults Aged ≥19 Years Who Currently Have a Recommendation to Receive a Pneumococcal Conjugate
Vaccine. 2024/09/12. https://www.cdc.gov/acip/grade/pcv21-adults-19-and-older.html (accessed 2026/7/31).
54.
Centers for Disease Control and Prevention. Grading of Recommendations, Assessment,
Development, and Evaluation (GRADE): 21-valent Pneumococcal Conjugate Vaccine (PCV21) Use among
Adults Aged 50–64 Years Who Currently Do Not Have a Risk-Based Pneumococcal Vaccine Indication.
2024/05/27. https://www.cdc.gov/acip/grade/pcv21-non-risk-based-adults-50-64.html (accessed 2026/7/31).
55.
Health Canada. Summary Basis of Decision for Capvaxive. 2025/04/04 2024. https://dhpp.hpfb-
dgpsa.ca/review-documents/resource/SBD1734463856248 (accessed 2026/7/31).
56.
European Medicines Agency. Capvaxive: EPAR - Public assessment report. 2025/01/30 2025.
https://www.ema.europa.eu/en/documents/assessment-report/capvaxive-epar-public-assessmentreport_en.pdf (accessed 2026/7/31).
33